Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma
Although treatment of multiple myeloma (MM) with daratumumab significantly extends the patient's lifespan, resistance to therapy is inevitable. ISB 1342 was designed to target MM cells from patients with relapsed/refractory MM (r/r MM) displaying lower sensitivity to daratumumab. ISB 1342 is a...
Glavni autori: | Pouleau, B, Estoppey, C, Suere, P, Nallet, E, Laurendon, A, Monney, T, Pais Ferreira, D, Drake, A, Carretero-Iglesia, L, Macoin, J, Berret, J, Pihlgren, M, Doucey, M-A, Gudi, GS, Menon, V, Udupa, V, Maiti, A, Borthakur, G, Srivastava, A, Blein, S, Mbow, ML, Matthes, T, Kaya, Z, Edwards, C, Edwards, JR, Menoret, E, Kervoëlen, C, Pellat-Deceunynck, C, Moreau, P, Zhukovsky, E, Perro, M, Chimen, M |
---|---|
Format: | Journal article |
Jezik: | English |
Izdano: |
American Society of Hematology
2023
|
Slični predmeti
-
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
od: Grandclément, C, i dr.
Izdano: (2024) -
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
od: C. Grandclément, i dr.
Izdano: (2024-03-01) -
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
od: Carretero-Iglesia, L, i dr.
Izdano: (2024) -
P871: ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES
od: C. Grandclement, i dr.
Izdano: (2022-06-01) -
Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity
od: Jeremy Loyau, i dr.
Izdano: (2025-12-01)